checkAd

    DGAP-News  838  0 Kommentare MOLOGEN AG submitted clinical study with MGN1703 in small cell lung cancer - Seite 3


    the Promotion of Science and Humanities in Germany | Association of
    German biotechnology companies (VBU) | Association of researching
    manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical
    industry e.V. (VCI)

    MIDGE(R), dSLIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG.

    MOLOGEN AG

    PRESS SERVICE:
    Prof. Peter W. Huebner
    Head of Corporate Communications
    Tel: +49 - 30 - 84 17 88 - 38
    Fax: +49 - 30 - 84 17 88 - 50
    huebner@mologen.com

    INVESTOR RELATIONS:
    Joerg Petrass
    Tel: +49 - 30 - 84 17 88 - 13
    Fax: +49 - 30 - 84 17 88 - 50
    investor@mologen.com

    External Investor Relations:
    Kirchhoff Consult AG
    Sebastian Bucher
    Tel: +49 - 40 - 60 91 86 - 18
    Fax: +49 - 40 - 60 91 86 -16
    sebastian.bucher@kirchhoff.de

    Note about risk for future predictions
    Certain information in this report contains forward-looking statements or
    the corresponding statements with negation or versions deviating from this
    or comparable terminology. These are described as forward-looking
    statements. In addition, all of the information given here that refers to
    planned or future results of business areas, key financial figures,
    developments of the financial situation or other financial figures or
    statistical data, is to be understood as such forward-looking statements.
    The company points out to investors that they should not rely on these
    forward-looking statements as predictions about actual future events. The
    company is not obligated and refuses to accept any liability for the
    forward-looking statements and has no obligation to update such statements
    in order to accurately reflect the current situation.


    End of Corporate News

    ---------------------------------------------------------------------

    28.10.2013 Dissemination of a Corporate News, transmitted by DGAP - a
    company of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    DGAP's Distribution Services include Regulatory Announcements,
    Financial/Corporate News and Press Releases.
    Media archive at www.dgap-medientreff.de and www.dgap.de

    ---------------------------------------------------------------------


    Language: English
    Company: MOLOGEN AG
    Fabeckstraße 30
    14195 Berlin
    Germany
    Phone: 030 / 841788-0
    Fax: 030 / 841788-50
    E-mail: info@mologen.com
    Internet: www.mologen.com
    ISIN: DE0006637200
    WKN: 663720
    Listed: Regulierter Markt in Frankfurt (Prime Standard);
    Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
    Stuttgart


    End of News DGAP News-Service
    ---------------------------------------------------------------------
    236376 28.10.2013
    Seite 3 von 3


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News MOLOGEN AG submitted clinical study with MGN1703 in small cell lung cancer - Seite 3 DGAP-News: MOLOGEN AG / Key word(s): Study MOLOGEN AG submitted clinical study with MGN1703 in small cell lung cancer 28.10.2013 / 08:00 --------------------------------------------------------------------- MOLOGEN AG submitted clinical study with …

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer